European Haemophilia Consortium (EHC) Communication on Particulate Matter in Emicizumab (Hemlibra®) and Other Biologic Agents
Background information: Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians and patients. While some particles can come from outside sources (e.g. when the […]